Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 7Lymphoma, B-Cell 4Lymphoma, Follicular 3Lymphoma 3Lymphoma, Mantle-Cell 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

venetoclax 69Cyclophosphamide 53ibrutinib 45obinutuzumab 43acalabrutinib 43Rituximab 40fludarabine 37fludarabine phosphate 30Specimen Handling 29pirtobrutinib 26Biopsy 24zanubrutinib 23Whole-Body Irradiation 16Bendamustine Hydrochloride 15Magnetic Resonance Spectroscopy 14Mycophenolic Acid 13Lenalidomide 11Peripheral Blood Stem Cell Transplantation 9Sirolimus 8idelalisib 7Tacrolimus 7CT-P10 7ARQ531 7tafasitamab 6Prednisone 6Busulfan 6pembrolizumab 5Stem Cell Transplantation 5Melphalan 5Interleukin-2 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × loncastuximab tesirine × 1 year × Clear all
NCT05971251 2025-10-01

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

University of Alabama at Birmingham

Phase 1 Active not recruiting
24 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡